OCGN - Ocugen

-

$undefined

N/A

(N/A)

Ocugen NASDAQ:OCGN Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Its breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug - "one to many" and its novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The Company is co-developing Bharat Biotech's COVAXIN™ vaccine candidate for COVID-19 in the U.S. market.

Location: 5 Great Valley Pkwy Ste 160, Pennsylvania, 19355, US | Website: ocugen.com | Industry: Sanitary Paper Product Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

192.6M

Cash

38.7M

Avg Qtr Burn

N/A

Short % of Float

18.41%

Insider Ownership

1.27%

Institutional Own.

27.53%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
OCU400 Details
Retinitis Pigmentosa

BLA

Submission

Phase 3

Initiation

OCU410 Details
Geographic atrophy, Age-related macular degeneration

Phase 1/2

Data readout

OCU400 Details
Eye disease , Leber congenital amaurosis

Phase 1/2

Data readout

OCU410ST Details
Stargardt disease, Rare genetic disease

Phase 1/2

Update

OCU200 Details
Diabetic macular edema

Phase 1

Data readout

COVAXIN (BBV152) Details
COVID-19, Infectious disease

Failed

Discontinued